Evaluation of Machine Learning Methods for Identifying Carbonic Anhydrase-II Inhibitors as Drug Candidates for Glaucoma
Malacca Pharmaceutics · 2025
DOI: 10.60084/mp.v3i1.271 ↗Kurz gefasst
Fachartikel in der Zeitschrift Malacca Pharmaceutics, 2025. Verfasst von Teuku Rizky Noviandy und 4 weiteren Autor:innen. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Glaucoma is a leading cause of irreversible blindness, primarily managed by lowering intraocular pressure (IOP). Carbonic Anhydrase-II (CA-II) inhibitors play a crucial role in this treatment by reducing aqueous humor production. However, existing CA-II inhibitors often suffer from poor selectivity, side effects, and limited bioavailability, highlighting the need for more efficient and targeted drug discovery approaches. This study uses machine learning-driven Quantitative Structure-Activity Relationship (QSAR) modeling to predict CA-II inhibition based on molecular descriptors, significantly enhancing screening efficiency over traditional experimental methods. By evaluating multiple machine learning models, including Support Vector Machine, Gradient Boosting, and Random Forest, we identify SVM as the most effective classifier, achieving the highest accuracy (83.70%) and F1-score (89.36%). Class imbalance remains challenging despite high sensitivity, necessitating further improvements through resampling and hyperparameter optimization. Our findings underscore the potential of machine learning-based virtual screening in accelerating CA-II inhibitor identification and advocate for integrating AI-driven approaches with traditional drug discovery techniques. Future directions include deep learning enhancements and hybrid machine learning-docking frameworks to improve prediction accuracy and facilitate the development of more potent and selective glaucoma treatments.
Zitieren
APA
Noviandy, T. R., Imelda, E., Idroes, G. M., Suhendra, R., & Idroes, R. (2025). Evaluation of Machine Learning Methods for Identifying Carbonic Anhydrase-II Inhibitors as Drug Candidates for Glaucoma. Malacca Pharmaceutics. https://doi.org/10.60084/mp.v3i1.271
Vancouver
Noviandy TR, Imelda E, Idroes GM, Suhendra R, Idroes R. Evaluation of Machine Learning Methods for Identifying Carbonic Anhydrase-II Inhibitors as Drug Candidates for Glaucoma. Malacca Pharmaceutics. 2025. doi:10.60084/mp.v3i1.271
BibTeX
@article{Noviandy2025,
author = {Noviandy, Teuku Rizky and Imelda, Eva and Idroes, Ghazi Mauer and Suhendra, Rivansyah and Idroes, Rinaldi},
title = {Evaluation of Machine Learning Methods for Identifying Carbonic Anhydrase-II Inhibitors as Drug Candidates for Glaucoma},
journal = {Malacca Pharmaceutics},
year = {2025},
doi = {10.60084/mp.v3i1.271}
}
EUVIMED